Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals has a dominant Cystic fibrosis franchise and plans to launch five new products by 2028, including a next-generation CF drug and a non-opioid pain management drug. VRTX stock has stalled in 2024 due to lower revenue growth projections for the year, which is unappealing for growth investors. The long-term potential of its drug pipeline may justify buying for long-term growth investors.

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

CRISPR Therapeutics

Novo Nordisk

Biopharma stocks have been among the most popular and well-performing stocks this year. With recent trends in weight loss drugs and clinical advancements in treating illnesses, this market is set for significant advances this year.

3 Biopharma Stocks Predicted to Soar in Q2 2024

Pyxis Oncology

Vir Biotechnology

Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.

From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires

HCA Healthcare

Vertex Pharmaceuticals is still making progress in its core area while diversifying its lineup. HCA Healthcare's entrenched position in its industry will help it benefit from long-term trends.

2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

Eli Lilly

Investors need not be concerned about the FDA's approval delay for Eli Lilly's Alzheimer's drug. Novo Nordisk recently picked up a regulatory win that makes the stock even more attractive.

3 Unstoppable Stocks You Can Buy Now Without Any Hesitation

Tesla faces an uncertain future as rising competition and shrinking margins are putting pressure on its business. Vertex Pharmaceuticals has a bright future ahead with multiple growth catalysts, which can bolster its top line.

Forget Tesla, Buy This Magnificent Healthcare Stock Instead

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Leerink Partners Global Biopharma Conference Call March 11, 2024 4:00 PM ET Company Participants Charlie Wagner - Executive Vice President & Chief Financial Officer David Altshuler - Chief Scientific Officer Conference Call Participants David Risinger - Leerink Partners David Risinger Good afternoon, everyone. My name is Dave Risinger.

Vertex Pharmaceuticals Incorporated (VRTX) Leerink Partners Global Biopharma Conference (Transcript)

Madrigal Pharmaceuticals

Regeneron Pharmaceuticals

Madrigal Pharmaceuticals could be days away from winning its first FDA approval. Regeneron Pharmaceuticals expects several key regulatory decisions this year.

Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.

Amylyx Pharmaceuticals

Investing in biotechnology (biotech) stocks is often thought of as being too risky for most investors. That's not necessarily the case.

The Top 3 Biotech Stocks to Buy in March 2024

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) TD Cowen 44th Annual Health Care Conference Call March 5, 2024 10:30 AM ET Company Participants David Altshuler - Executive Vice President, Research and Chief Scientific Officer Charlie Wagner - Executive Vice President and Chief Financial Officer Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good morning, and welcome once again to TD Cowen's 44th Annual Healthcare Conference. I am Phil Nadeau, one of the biotech analysts, and it's my pleasure to moderate a fireside chat with Vertex, one of the bellwethers of the industry.

Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 44th Annual Health Care Conference (Transcript)

GlaxoSmithKline

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with GSK (GSK) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?

GSK vs. VRTX: Which Stock Is the Better Value Option?

COMPASS Pathways

Catalyst Pharmaceuticals

Vertex Pharmaceuticals is angling to treat acute pain with its new drug. Compass Pathways will have a major data update sometime in Q4.

3 Biopharma Stocks You Don't Want to Miss in the New Bull Market

United Therapeutics

The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment opportunities in 2024.

Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making

Biogen

If you're looking for biotech stocks to buy, the iShares Biotechnology ETF (NASDAQ: IBB ) is an excellent place to start. It tracks the performance of the ICE Biotechnology Index, a collection of U.S. companies in the biotech industry.

Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits

Moderna

ChatGPT stock predictions could be more than shots in the dark by AI. The processing and inferential power of artificial intelligence progresses seemingly exponentially every day.

ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential

Eli Lilly could have the world's future best-selling drug in its lineup. Moderna is poised to expand beyond COVID with several new products potentially on the way.

3 Magnificent Growth Stocks to Buy in March

Intuitive Surgical

The Magnificent Seven are stealing the show this year on the market. They're all technology companies -- but there are opportunities elsewhere, too.

These 4 Stocks Are the "Magnificent Seven" of Healthcare

Vertex, Eli Lilly, and Novo Nordisk have many of the traits of the "Magnificent Seven." All three biotech stocks should continue delivering outsized returns for a long time.

Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks?

Vertex Pharmaceuticals has seen impressive growth, with shares increasing by 14% and returning over 50% in the past year. The company's strong portfolio and pipeline have contributed to its consistent double-digit growth for the past nine years. Vertex has invested a significant amount in R&D and acquisitions, supporting its innovation and future commercial launches.

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Viking Therapeutics

Biotech stocks have long been a speculative, albeit rewarding way to invest in the advancement of medical technology. This industry has a wide range of companies, from start-up firms that are researching their first treatment to pharmaceutical giants that are among the largest and most powerful companies in the world.

3 Biotech Stocks Bound to Blast Off By 2029

Amazon

Healthcare and tech spending continues to roar to new levels of growth. Vertex Pharmaceuticals is working to change the standard of care for multiple rare diseases, a feat it's already proven it can successfully accomplish.

2 Stocks That Could Crush the Market in 2024

Lennar

Royal Caribbean Cruises

S&P 500 stocks Lennar, Vertex Pharmaceuticals and Royal Caribbean lead this list of five stocks trading around buy points.

Three S&P 500 Giants Lead This List Of Stocks Near Buy Points

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants with cystic fibrosis (CF) ages 1 month to less than 4 months old who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G5.

Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older

Alphabet

PayPal

Alphabet is a leader in two technologies that could transform the future. PayPal is a dirt cheap fintech leader with a stronger business than you might think.

The Best Stocks to Invest $5,000 in Right Now

UiPath

Science Applications International

Uncovering the illusive secrets with stocks to double your money is an endeavor that captures the imagination of many. But the quest for lucrative opportunities becomes increasingly challenging with the constant noise.

News for Vertex Pharmaceuticals Stock (VRTX)